The Wager
GSK announced Tuesday it will pay $58 per share—a 65% premium—to acquire RAPT Therapeutics for $2.2 billion in equity value, or $1.9 billion net of cash. The deal, expected to close in the first quarter, hands GSK global rights to ozureprubart, an experimental antibody designed to protect patients from food allergies with injections every 12 weeks instead of the current standard of every two to four weeks.
What makes this deal remarkable is the timing: GSK is writing a check two years before knowing whether the drug actually works. Phase IIb trial results won't arrive until 2027, meaning the company is paying today for a hypothesis about patient convenience, not clinical proof.
What GSK Is Actually Buying
Strip away the press release language about "best-in-class" potential, and the acquisition becomes clearer: GSK is not buying a new mechanism or a revolutionary approach to food allergies. It's buying a durability play against an already-approved competitor.
The target—immunoglobulin E—is thoroughly validated. Roche and Novartis's omalizumab already holds FDA approval for IgE-mediated food allergies, the same condition ozureprubart targets. Roughly 94% of severe food allergies stem from IgE-mediated reactions, affecting over 17 million Americans and driving more than 3 million emergency room visits annually.
GSK's entire differentiation thesis rests on extending the dosing interval from Xolair's two-to-four-week schedule to 12 weeks, potentially improving compliance among the mostly pediatric patient population. The company also claims ozureprubart could serve approximately 25% of patients currently ineligible for existing therapy, though this figure requires real-world validation.
The Convenience Gamble
Here lies the central tension: in biologic treatments where the mechanism is de-risked, convenience commands premium pricing—but only if efficacy doesn't suffer. If ozureprubart's quarterly regimen produces materially lower protection or inconsistent response rates compared to Xolair, the "less frequent dosing" advantage evaporates.
The Phase IIb prestIgE trial is evaluating both eight-week and 12-week schedules using oral food challenge endpoints. These measurements are clinically meaningful but notoriously noisy, vulnerable to site execution variability and patient selection heterogeneity. The crucial gating question: Can ozureprubart maintain Xolair-level protection through the dosing trough at 12 weeks without introducing safety constraints that would eliminate the adherence benefit?
Any "end-of-interval leakage"—breakthrough allergic reactions as drug levels wane—would demolish the convenience premium GSK is banking on.
The Financial Calculation
At $1.9 billion net for a mid-stage asset with no revenue and uncertain clinical trajectory, GSK is paying a steep price by industry standards. RAPT reported $52.4 million in net losses for the nine months ended September 2025, with substantial expenditures ahead for pipeline expansion.
Yet the acquisition aligns with Chief Scientific Officer Tony Wood's stated approach: "acquire assets that address validated targets and where there is clear unmet medical need." GSK has aggressively pursued immunology as a growth pillar, recently entering a potential $12 billion partnership with Hengrui Pharma and targeting £20 billion in annual sales from its late-stage pipeline.
The deal math essentially boils down to GSK paying today for the option that ozureprubart becomes a market disruptor. If it merely achieves "similar but not better" status against Xolair, the company will have purchased an expensive also-ran.
Market reaction reflected this uncertainty: RAPT shares surged 63% to $57.51, while GSK shares declined 0.96%.
The Broader Implications
This marks one of 2026's first major biopharmaceutical transactions, signaling renewed merger activity following the JP Morgan Healthcare Conference. The food allergy treatment market, valued at approximately $6.5 billion to $7 billion currently, is projected to reach $11 billion to $15 billion by 2030.
But prevalence doesn't automatically translate to treatment volume. Payers will demand evidence of risk reduction and acute care cost savings. The pediatric market offers the highest adherence benefit but also faces the toughest regulatory scrutiny on long-term safety.
GSK has bought itself a shot at disrupting a validated market through operational improvement rather than scientific breakthrough. Success depends entirely on execution—proving that longer intervals don't compromise protection. The answer arrives in 2027.
NOT INVESTMENT ADVICE